Business
Sutro Biopharma Announces Appointment of Jon M. Wigginton, M.D., to Board of Directors
- Dr. Wigginton, leader in immuno-oncology and CMO at Cullinan Oncology, to bring additional strategic expertise to Sutro's Board - SOUTH SAN FRANCISCO,
About this update from Sutro Biopharma, Inc.
[{"type":"text","content":"- Dr. Wigginton, leader in immuno-oncology and CMO at Cullinan Oncology, to bring additional strategic expertise to Sutro's Board -\n\n\nSOUTH SAN FRANCISCO, Calif., Dec. 1, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Jon M. Wigginton, M.D., has been appointed to Sutro's Board of Directors. \n\"As a seasoned global pharmaceutical leader with a passion for drug development and expertise in oncology, Jon brings a wealth of experience to the Board,\" said Bill Newell, Sutro's Chief Executive Officer. \"His impressive successes in leading programs and bridging basic science, translational medicine, and clinical research will be readily transferable to our clinical pipeline of antibody drug-conjugates and our developmental pipeline, including a next-generation approach utilizing Sutro's XpressCF® and XpressCF+™ technologies to take antibody drug-conjugates into the future.\"\n\"We are very pleased to welcome Jon to the Sutro Board of Directors at this important time in the Company's journey,\" said Connie Matsui, Chair of Sutro's Board of Directors. \"Jon's experience in immuno-oncology and in advancing scientific discoveries to the clinic make him an invaluable addition to our Board as Sutro continues to develop its proprietary pipeline and grow partnerships to expand the reach of Sutro's novel therapeutics and technology.\"\nDr. Wigginton is a physician and scientist with expertise in cancer immunotherapy drug development. \nHe has over 25 years of experience in clinical oncology, with leadership experience in both academia and industry. Dr. Wigginton is currently Chief Medical Officer of Cullinan Oncology, LLC. and an advisor to MPM Capital. Prior, he was Chief Medical Officer at MacroGenics, where he led the company's clinical development programs. Dr. Wigginton also held leadership positions at Bristol Myers Squibb as Therapeutic Area Head in Immuno-Oncology for Early Clinical Research and as Executive Medical Director and Group Medical Director of Discovery Medicine-Clinical Oncology, and prior to that, Director of Clinical Oncology at Merck & Co. Dr. Wigginton has also served in sever...